Compare HOVR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ALXO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 68.3M |
| IPO Year | N/A | 2020 |
| Metric | HOVR | ALXO |
|---|---|---|
| Price | $1.82 | $1.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $10.33 | $3.00 |
| AVG Volume (30 Days) | 454.6K | ★ 721.1K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.41 |
| 52 Week High | $4.18 | $2.66 |
| Indicator | HOVR | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 45.26 |
| Support Level | $1.70 | $1.41 |
| Resistance Level | $1.90 | $2.31 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 27.14 | 1.45 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.